Vascular Complications of Atrial Fibrillation in Patients With Cancer.

Competing Interests: Funding Support and Author Disclosures Dr Gervaso is a consultant or an advisory board member for Gilead (not related to this work). Dr Cardinale has received consultant and speaker fees from Siemens Healthineers, Ipsen, and Gilead Sciences (not related to this work). Dr Fazio has received honoraria for consulting, advisory roles, Speakers Bureau membership, travel, and/or research grants from Merck Sharp & Dohme, Novartis, AstraZeneca, Roche, Menarini, Daiichi-Sankyo, GlaxoSmithKline, Gilead, Diaceutics, Adicet Bio Sermonix, Reply, and Leica Biosystems; has financial interests in, has personal interest in, and is an invited speaker for Merck Sharp & Dohme, AstraZeneca, Daiichi-Sankyo, GlaxoSmithKline, Gilead, Novartis, Roche, Menarini, Eli Lilly, and Sysmex; has financial interests in, has personal interest in, and is an advisory board member for Merck Sharp & Dohme, AstraZeneca, and Menarini; has financial interests in, has personal interest in, and has received institutional research grants from Novartis, Sysmex, and Veracyte (not related to this work).